SEVION THERAPEUTICS, Inc. Consulting AgreementConsulting Agreement • February 17th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • California
This Consulting Agreement (this “Agreement”) is entered into as of January 9, 2015 (the “Effective Date”), by and between Sevion Therapeutics, Inc., or successor thereof (the “Company”), and The David Stephen Group LLC, a limited liability company with a primary address as set forth on the signature page hereto (“Consultant”).
SUBLEASE AGREEMENTSublease Agreement • February 17th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • California
This Sublease Agreement (“Sublease”) is made as of the 10th day of October, 2014, by and between Pathway Genomics Corporation, a Delaware corporation (“Sublandlord”), and Fabrus, Inc., a wholly-owned subsidiary of Senesco Technologies, Inc., a Delaware corporation (“Subtenant”).
RETENTION AGREEMENTRetention Agreement • February 17th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New Jersey
This Retention Agreement (this “Agreement”) is made and entered into as of November 17, 2014 (the “Effective Date”), by and between Sevion Therapeutics, Inc., a Delaware corporation (the “Company”) and Richard Dondero (“Executive”).
COLLABORATION AND OPTION AGREEMENTCollaboration and Option Agreement • February 17th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • California
Royalty Term Janssen’s obligation to pay a royalty under this agreement for a Licensed Product in a given country shall be in effect in each country of sale from First Commercial Sale in the country and shall expire, on a country-by-country basis, on the later of ***. Janssen shall have the right to terminate the License Agreement at any time upon ninety (90) days’ advance notice. The License Agreement shall also include other standard termination provisions.
RETENTION AGREEMENTRetention Agreement • February 17th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New Jersey
This Retention Agreement (this “Agreement”) is made and entered into as of November 17, 2014 (the “Effective Date”), by and between Sevion Therapeutics, Inc., a Delaware corporation (the “Company”) and Heather Branham (“Employee”).
